Curevac Reaffirms Its Expected Cash Runway Into 2028
Reuters
Nov 24
Nov 24 (Reuters) - CUREVAC NV <5CV.DE>:: *CUREVAC Q3 REVENUE EUR 54.1 MILLION VERSUS. IBES ESTIMATE EUR 3.34 MILLION *CUREVAC Q3 EBIT EUR 310.2 MILLION *CUREVAC NV - COMPANY REAFFIRMS ITS EXPECTED CASH RUNWAY INTO 2028 *CUREVAC NV - GERMAN FEDERAL CARTEL OFFICE CLEARS BIONTECH-CUREVAC DEAL *CUREVAC NV - NET FINANCIAL RESULT FOR THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025, WAS LOSS OF EUR 2.6 MILLION AND GAIN OF EUR 2.2 MILLION, RESPECTIVELY
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.